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APC – antigen presenting cells 40 
DC – Dendritic cell 41 
DTH – delayed-typed hypersensitivity 42 
EBV – Epstein bar virus 43 
ELISPOT - enzyme linked immunosorbent spot 44 
mAb – monoclonal antibody 45 
MLR – Mixed leukocyte reaction 46 
moDC – monocyte-derived dendritic cells 47 
PBMC – peripheral mononuclear blood cells 48 
PHA - phytohemagglutinin  49 
SAL – single antigen lines 50 
TLR – Toll like receptor 51 
Treg – Regulatory T-cells 52 
53 
Page 3 of 31


































































Background: Recognition of donor antigens can occur through two separate pathways: 55 
the direct pathway (non-self HLA on donor cells) and the indirect pathway (self-restricted 56 
presentation of donor derived peptides on recipient cells). Indirect allorecognition is 57 
important in the development of humoral rejection, therefore there is an increasing 58 
interest in the monitoring of indirect alloreactive T-cells. We have used an in vitro model 59 
to determine the optimal requirements for indirect presentation and assessed the risk for 60 
semi-direct presentation in this system.  61 
 62 
Methods: HLA typed monocyte-derived dendritic cells (moDC) were incubated with 63 
cellular fragments or necrotic cells and incubated with either indirect or direct 64 
alloreactive T-cell clones. T-cell reactivity was measured by proliferation or cytokine 65 
secretion. HLA-typed moDC, monocytes or PBMCs were incubated with HLA class I 66 
monomers, in combination with either direct/indirect T-cell clones. 67 
 68 
Results: Although both were efficiently taken-up, alloreactivity was limited to the semi-69 
direct pathway, as measured by allo-specific CD4 (indirect) and CD8 T-cell clones 70 
(direct). In contrast, HLA-A2 monomers were not only efficiently taken up, but also 71 
processed and presented by HLA-typed moDC, monocytes or PBMCs. Activation was 72 
shown by a dose dependent induction of IFN-γ production and proliferation by the CD4 73 
T-cell clone. Antigen presentation was most efficient when the monomers were cultured 74 
for longer time periods (24-48h) in the presence of the T-cells. Using this method, no 75 
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reactivity was observed by the CD8 T-cell clone, confirming no semi-direct 76 
alloreactivity.  77 
 78 
Conclusion: we have developed a system that could be used to monitor indirect 79 
alloreactive T-cells.  80 
81 
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Transplantation has become the standard therapy in end stage renal failure, leading to an 83 
increase in quality of life and survival (1). Despite immunosuppressive regimes that are 84 
very effective in reducing acute rejection, chronic rejection remains a major cause of 85 
allograft loss (2).  86 
T-cells are a major driving force in mediating allograft rejection (3). Recipient CD4+ T-87 
cells can recognize the allograft either through recognition of donor HLA-peptide 88 
complexes on donor antigen presenting cells (APC, direct), or by recognizing self-89 
restricted donor HLA-derived peptides on recipient APCs (indirect). A third pathway 90 
(semi-direct) has been postulated in which recipient T-cells recognize intact donor HLA-91 
peptide complexes on recipient APCs (4, 5).  92 
T-cells with direct alloreactivity have been shown to play a dominant role in acute 93 
rejection, primarily in the early phase after transplantation, when APCs from donor origin 94 
are still available (6-8). T-cells with indirect alloreactivity are correlated with chronic 95 
rejection in humans (7, 9, 10). The importance of indirect allorecognition in allograft 96 
rejection is multiple and was recently reviewed (11). Briefly, it can provide help and thus 97 
induce alloreactive cytotoxic CD8 T-cells (12, 13). Perhaps more importantly indirect 98 
alloreactive CD4 T-cells are the only cells that can provide help to alloreactive B-cells as 99 
shown in animal models (13-15). These cells have also been implicated in the regulation 100 
of tolerance (16). Regulatory T-cells (Treg) from transplant recipients were shown to 101 
have indirect alloreactivity (17, 18). Furthermore, they were capable of suppressing both 102 
the direct and indirect pathways of allorecognition (19). Animal studies have shown that 103 
Treg with indirect allospecificity can abrogate alloantibody formation and mediate 104 
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transplant tolerance (20-22). Recently, natural Treg were shown to inhibit direct but not 105 
indirect allorecognition (23) Although both pathways have been known for decades, 106 
assays monitoring indirect T-cell alloreactivity have not become routine, and as of yet no 107 
clinical assay is available (11). 108 
Methods to monitor direct alloreactivity include the mixed leukocyte reaction (MLR), the 109 
cytotoxic T-cell precursor assay and more recently, the IFN-γ enzyme linked 110 
immunosorbent spot (ELISPOT). The assays give a good indication of the potency of 111 
directly reactive T-cells (24-27). Methods to measure indirectly reactive T-cells have 112 
been previously reviewed and offer many complications (28). These include the use of 113 
donor cell fragments as a source of donor antigens, which are presented in the context of 114 
self-HLA class II. In theory this method allows the full repertoire of alloantigen available. 115 
In practice, this assay is difficult and not very reproducible. Furthermore, reactivity may 116 
be due to the semi-direct pathway (29, 30). Synthetic peptides which correspond with the 117 
mismatched donor antigens have also been used (31-33). This method has a higher 118 
reproducibility but reactivity may be directed at neo-epitopes that are not available in 119 
vivo. The third method makes use of the trans vivo delayed-type hypersensitivity (DTH) 120 
model, in which recipient cells and donor cellular fragments are injected into the footpad 121 
of naïve mice (34-36). Donor cell alloreactivity leads to a DTH response that can be 122 
measured by the footpad swelling. The advantage is that a global alloresponse can be 123 
measured (37). However, this approach is very complex and technically too difficult to be 124 
used as a diagnostic assay. 125 
The aim of this study was to develop a reliable and easy tool to monitor indirect 126 
allorecognition in renal transplant patients that could be used in a clinical setting.  127 
128 
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Evidence for semi-direct rather than indirect allorecognition when donor cell 130 
fragments are used as exogenous antigen source 131 
To set-up and validate a model for indirect allopresentation, a previously characterized 132 
CD4 T-cell clone (referred to as 4.44) recognizing HLA-A2 peptide restricted by HLA-133 
DR1was used (38). Incubation of 4.44 with its native ligand in the form of Epstein Bar-134 
Virus (EBV) transformed B-cell line (EBV-LCL) expressing HLA-DR1 and HLA-A2 led 135 
to IFN-γ secretion (Figure 1A). Clone 4.44 did not react with HLA-DR1+/HLA-A2- 136 
EBV-LCLs, but IFN-γ secretion could be induced when cells were pulsed with HLA-A2 137 
peptides containing the relevant epitope (Figure 1B).  138 
A CD8 T-cell clone (referred to as 1E2) that recognizes HLA-A2 (39), was used as a 139 
readout to exclude semi-direct alloreactivity. Both T cell clones were cultured with single 140 
antigen lines (SAL) expressing only HLA-A2 (SAL-A2). T-cell reactivity as measured by 141 
IFN-γ was limited to the 1E2 T-cells, confirming specificity of both clones (Figure 1C).  142 
To investigate the process of indirect alloreactivity, monocyte-derived dendritic cells 143 
(moDC) from HLA-typed donors (HLA-DR1+/HLA-A2-) were used as APCs and were 144 
loaded with peptides or fragmented SAL-A2 cells as antigen source. After 48h clone 4.44 145 
was added, but apart from the positive control no indirect alloreactivity could be 146 
measured in any of the conditions (Figure 1D). In contrast, under similar conditions of 147 
loading fragments, when clone 1E2 was used low but significant production of IFN-γ 148 
could be detected in 3 out of 5 experiments (Figure 1E). This indicates that the use of cell 149 
fragments might result in semi-direct allorecognition when co-cultured with moDC. No 150 
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reactivity was observed when fragments and 1E2 were cultured alone. 1E2 activation was 151 
confirmed in all conditions where viable SAL-A2 were used.  152 
 153 
Processing of necrotic cells leads to semi-direct allorecognition 154 
Professional APCs have specialized mechanisms for the uptake of apoptotic or necrotic 155 
cells. Therefore, we investigated whether dead cells could be a more efficient way of 156 
loading alloantigen, without the risk of semi-direct allorecognition. Viable, or necrotic 157 
SAL-A2 cells were used as previously described (40). HLA-A2 expression on SAL-A2 158 
was confirmed on viable and necrotic (Nec) SAL-A2 (Figure 2A). Moreover, SAL-A2 159 
were stimulated with IFN-γ to increase HLA-A2 expression on these cells (Figure 2B). 160 
Uptake of dead cells, but not viable cells, was confirmed by flow cytometry as well as 161 
confocal microscopy (Figure 2C-D). Importantly, after 24h incubation a near complete 162 
removal of dead material was observed. This was an active process that did not occur at 163 
4°C.  164 
Indirect allorecognition studies were performed using HLA-A2-/HLA-DR1+ typed 165 
moDC. Whereas strong IFN-γ production was achieved with exogenous peptide loading 166 
none of the conditions investigated resulted in detectable activation of the 4.44 clone 167 
(Figure 2E). Activation of moDC using different toll-like receptor (TLR) ligands did not 168 
result in detectable indirect presentation (data not shown). Comparable to the fragments, 169 
a low albeit significant response was found for semi-direct allorecognition by 1E2 when 170 
necrotic SAL-A2 cells were used (Figure 2F).  171 
 172 
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HLA monomers can be used for antigen loading resulting in indirect allo-173 
presentation 174 
As an alternative source of alloantigens we investigated the potential use of HLA-A2 175 
monomers. Incubation of HLA-DR1+/HLA-A2- moDC with HLA-A2 led to potent 176 
activation of clone 4.44 comparable to exogenously loading of peptides (Figure 3A).  177 
This response was dose-dependent and significant IFN-γ production was observed with 178 
concentrations starting at 1µg/ml HLA-A2 and kept increasing until 125µg/ml (Figure 179 
3B). 180 
MoDCs were incubated with 25µg/ml HLA-A2 for various time points and after 181 
extensive washing 4.44 was added for an additional 24h. The highest reactivity was 182 
observed when moDCs were incubated for at least 4h with the antigen (Figure 3C). Next, 183 
moDCs were incubated with HLA-A2 for 4h before extensive washing. 4.44 T-cells were 184 
then added at 0h, 24h, or 48h and incubated for an additional 24h (Figure 3D). The 185 
highest reactivity was observed when 4.44 were added immediately (0h), while a steady 186 
decrease was observed after 24 and 48h, indicating a steady turnover of HLA-peptide 187 
complexes.  188 
As mMonocytes are the major a more readily available source of APCs within the 189 
PBMCs, we investigated their capacity to present alloantigens via the indirect pathway. 190 
Similarly to moDC, monocytes showed a strong capacity to present HLA-A2 and activate 191 
4.44 T-cells, comparable to the exogenous peptide (Figure 3E-F). This response was 192 
dose-dependent and significant levels of IFN-γ were observed at concentrations of 193 
1µg/ml HLA-A2, reaching an optimum at 25µg/ml (Figure 3F).  194 
 195 
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PBMCs can present monomer derived peptides to indirect allorecognizing T-cells 196 
clones without evidence for semi-direct allorecognition 197 
Since the afore mentioned experiments were performed with purified populations, we 198 
next addressed the question whether the use of total PBMC would affect the sensitivity or 199 
specificity of the above described model. HLA-DR1+/HLA-A2- PBMCs were pulsed 200 
with HLA-A2 peptides or incubated with HLA-A2 monomers in the presence/absence of 201 
4.44. Again using either exogenous peptide or HLA-A2 monomers, a strong and dose-202 
dependent response of the T-cell clone could be detected (Figure 4A-B). In the absence of 203 
the T-cell clone no IFN-γ production could be detected indicating that the addition of 204 
HLA-A2 monomer does not activate CD8 T-cells with direct allospecificity (Figure 4A). 205 
The absence of semi-direct allorecognition could be further confirmed with the 1E2 206 
clone, which was completely unresponsive when incubated with the HLA-typed PBMCs 207 
and increasing concentrations of HLA-A2, as depicted by IFN-γ production as well 208 
proliferation (Figure 4C-D). This is in stark contrast to clone 4.44 which was highly 209 
positive in both conditions. 210 
To investigate the sensitivity of this model, various PBMCs concentrations were tested 211 
and incubated for 24 or 48h with a set amount of HL-A2 and 4.44 (Figure 4E). 48h and 212 
1x10
5
 PBMCs yielded overall a better T-cell response. When titrating the T cell clone, as 213 
little as 8-40 T-cells were sufficient to induce detectable levels of IFN-γ when 1x10
5
 214 
PBMCs were incubated with 25µg/ml HLA-A2 for 48h (Figure 4F). 215 
Finally, we could confirm that antigen presentation was completely HLA-DR dependent. 216 
The cytokine production and proliferation was completely and dose-dependently 217 
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prevented when cultures with 4.44 were incubated with a blocking antibody against 218 
HLA-DR (Figure 4G-H).  219 
220 
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Indirect allorecognition is considered one of the important factors in mediating chronic 222 
allograft rejection and influencing long term graft outcome (7, 41-43). However, at the 223 
moment, no reliable test is available to monitor indirect allorecognition in organ 224 
transplant recipients. A major hurdle is the antigen loading, that requires a high 225 
sensitivity to detect low frequency indirect T-cells, and a high specificity to exclude T-226 
cells with direct specificity. In the current study, we have successfully developed a novel 227 
in vitro method to measure indirect allorecognition. By using T-cell clones that 228 
specifically recognize HLA-A2 through the indirect (HLA-A2 peptides restricted by 229 
HLA-DR1) or direct (HLA-A2) pathway of allorecognition, we could demonstrate that 230 
semi-direct allorecognition is not an issue in our model system, where HLA-A2 231 
monomers were used as a source of alloantigen. 232 
In experiments using HLA-A2 expressing cells as donor antigen source (either as cell 233 
fragments or as necrotic cell) reactivity was limited to the semi-direct pathway of 234 
alloreactivity. This raises some questions on the conclusions drawn from previous studies 235 
that have routinely used cellular fragments to measure indirect alloreactivity (7, 10, 44). 236 
Those studies did not include controls to distinguish between semi-direct and indirect 237 
allorecognition and it is therefore possible that the semi-direct pathway has a contribution 238 
to the allorecognition measured in those studies.  239 
The semi-direct pathway involves the incorporation of alloantigen intact on the cell 240 
surface and has been shown to occur with DCs (45) monocytes and T-cells (46, 47). The 241 
process of membrane transfer is a subject of many studies and the mechanisms involved 242 
are now slowly unraveled (48). Interestingly, cross-dressed DCs (DCs that express an 243 
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acquired HLA-peptide complex) have been shown to prime CD8 T-cells in mice (45, 49). 244 
This suggests that semi-direct allorecognition could potentially lead to T-cell priming, 245 
which is an important factor in interpreting model systems that use cell fragments or 246 
apoptotic and necrotic cells to monitor indirect allorecognition. Reactivity against HLA 247 
class I molecules was observed in 3 out of 5 experiments preformed. The reactivity was 248 
limited to low levels of IFN-γ and is most likely due to the limited HLA class I molecules 249 
transferred. The conditions in most experiments involving membrane transfer are short 250 
term (2h), it is possible that longer time periods (as utilized in our experiments) reduce 251 
the efficiency, and thereby the reactivity. However, we observed no indirect alloreactivity 252 
in any of the conditions utilizing cellular fragments, or dead cells. Although the material 253 
is taken-up and processed there is relative little HLA class I molecules when compared 254 
with all other proteins available, that will also be processed and presented and therefore 255 
will generate large amounts of competing peptides that will not be recognized by the T 256 
cell clone. Furthermore, the T-cell clone only recognizes one epitope in the context of 257 
HLA class II, while the APC presents multiple epitopes which might not be recognized 258 
by the T-cell clone.  259 
Another strategy to monitor indirect presentation has been the use of synthetic peptides. 260 
In vivo APCs present donor derived peptides to autologous T-cells restricted by their own 261 
HLA class II molecules. Each HLA class II molecule has its own repertoire of peptides 262 
that can be presented. Prediction of HLA class II epitopes, is complex and it is unlikely 263 
that a set of peptides can be used to predict individual alloreactivity (50). Current tests 264 
that use synthetic peptides have the risk of creating neo-epitopes, epitopes that are not 265 
created in the natural antigen processing manner (31-33, 51). This may even lead to 266 
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reactivity to peptides derived from autologous HLA molecules. Peptides used for the 267 
detection of indirect allorecognition include peptides derived from the β1 domain of HLA 268 
class II (32, 51-53) or the α1 domain of HLA class I (33, 54). In one study, where 269 
peptides from a complete HLA-A2 molecule were used, reactivity was seen in the 270 
hypervariable region as well as from the α3 subunit and the trans-membrane domain (52). 271 
However, as no peptides from self-HLA were taken as a control it is unclear what the 272 
reactivity means, and whether these peptides would be formed when naturally processed. 273 
Use of longer peptides could be a good alternative, as these would require processing and 274 
are able to induce T-cell reactivity in other model systems of antigen presentation (53, 275 
54). 276 
HLA monomers offer solutions to many of the problems depicted earlier. However, there 277 
are two distinct disadvantages in using monomers. The one is the high price involved in 278 
making highly pure monomers and secondly the relatively high concentration needed to 279 
induce a reproducible T-cell response.  280 
The quest to induce long-term graft tolerance and/or survival starts with an accurate 281 
depiction of the recipient’s immune-response against the donor allograft. Although many 282 
studies are aimed at monitoring and measuring operational tolerance and organ rejection 283 
(55, 56), no reliable test exists other than the actual clinical outcome. Measuring indirect 284 
allorecognition could give a broad view into how the recipient immune-system is shaping 285 
its response to the allograft and be helpful in tailoring an individual immune-suppression 286 
regime to prolong graft survival.  287 
288 
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Materials and methods 289 
Cell culture and reagents 290 
Peripheral blood mononuclear cells (PBMC), monocytes and monocytes-derived 291 
dendritic cells (moDC) were cultured in RPMI-1640 (PAA, Austria) supplemented with 292 
10% FCS (Bodinco, the Netherlands), 5,000 U/ml penicillin and 5 mg/ml streptomycin 293 
(Invitrogen, USA). 294 
Single antigen lines (SAL) were created by transfecting K562 cells with a plasmid 295 
construct containing a HLA-A2 heavy chain gene (SAL-A2) (57). SAL-A2 were 296 
maintained in IMDM supplemented with 10% FCS, pen/strep and G-418 (Roche, 297 
Germany) at a concentration of 250 µg/ml for the selection of stably transfected SALs.  298 
HLA-A*0201 derived peptides of the region 99-122 of HLA-A2 were synthesized. HLA-299 
A*0201 heavy chains were produced in E.coli. Monomer refolding around the 300 
melanoma-associated pmel 17 peptide (YLEPGVTA) in the presence of β2-301 
microglobulin was achieved as previously described (58). Monomers were purified by gel 302 
filtration HPLC and tested routinely.  303 
T-cells clones 4.44 (CD4+) and 1E2 (CD8+), recognizing HLA-A2 (aa98-120) restricted 304 
by HLA-DR1 and HLA-A2 respectively, have been previously described (38, 59). They 305 
were maintained in IMDM medium (PAA, Austria) with 5% FCS (Bodinco, the 306 
Netherlands), 5% normal human serum (Sanquin, the Netherlands), 100 IU/ml 307 
recombinant IL-2 (Chiron, Novartis, USA) 5,000 U/ml penicillin, 5 mg/ml streptomycin, 308 
and 2 mM L-glutamine (Gibco, invitrogen, USA). Expansion was achieved by 309 
stimulation with phytohemagglutinin (PHA, 0.8 µg/ml, Murex Biotec Limited, Dartford, 310 
UK) and PBMCs in a ratio of 1:5. Cells were harvested after two weeks and either frozen 311 
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or used in experiments after a resting period of 2-3 days. T-cell specificity was routinely 312 
tested. 313 
Stable Epstein-Barr virus (EBV)-transformed B-cell lines (EBV-LCL) were generated 314 
from an HLA-DR1+/HLA-A2- donor using standard procedures (60). HLA-A2+ EBV-315 
LCLs were generated by transducing a retroviral vector encoding for HLA-A*0201 into 316 
the donor (HLA-A2-) EBV-LCLs (61).  317 
 318 
Generation of monocytes-derived dendritic cells 319 
moDCs were generated from buffy coats as previously described (62). Briefly PBMCs 320 





) individuals using Ficoll/amidotrizoaat (pharmacy, LUMC, the Netherlands) 322 
density gradient, followed by CD14 microbeads magnetic cell sorting (Miltenyi Biotec, 323 
The Netherlands) according to manufactures protocol. Monocytes were cultured in 6 well 324 
plates (Costar, USA) in RPMI-1640 supplemented with 10 ng/ml IL-4 and 5 ng/ml GM-325 
CSF (Gibco, Invitrogen, USA). Cytokines were refreshed every 2-3 days and cells were 326 
allowed to differentiate for at least 6 days before harvesting.  327 
 328 
Indirect allorecognition assay using cells as source of HLA class I antigens 329 
moDCs were co-cultured with necrotic, apoptotic or fragmented SAL-A2 cells. Necrosis 330 
and apoptosis was induced as previously described (40). Briefly necrosis was induced by 331 
heating cells to 56°C for one hour and confirmed by light microscopy and annexin-V/PI 332 
staining. Cell fragments were generated by 3 rounds of freeze-thawing and confirmed by 333 
light microscopy. 5x10
5
 moDCs were co-cultured at a 1:1 ratio with SAL-A2 cells for a 334 
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period of at least 24h in a 96 round well plate. 5x10
3
 4.44 cells (CD4 indirect) or 1E2 335 
(CD8 direct/semi-direct) cells were added for an additional 48h incubation. Supernatants 336 
were then harvested and IFN-γ production was measured. 337 
 338 
Phagocytosis assay 339 
Phagocytosis was quantified by flow cytometry or fluorescence microscopy as previously 340 
described (40). Briefly moDCs were labeled with PKH26 (Sigma-Aldrich) or stained 341 
with HLA-DR mAb. Necrotic, apoptotic or fragmented SAL-A2 cells were stained with 342 
CFSE prior to induction of cell death and then co-cultured with moDCs at a ratio of 1:1 343 
(5x10
4
 cells). Analysis was conducted at 2 or 24h post co-culture. Fluorescence was 344 
assessed with FACSCalibur or LSR-II or with a Leica SP5 confocal scanning laser 345 
microscope and the analysis preformed with ImageJ imaging software.  346 
 347 
Indirect/direct allorecognition assay using HLA class I monomers 348 







) in round 96-well plates (Costar, USA) and incubated with different 350 
concentrations of HLA-A2 monomers (HLA-A2) or peptides. T-cells were added to the 351 
culture (5x10
3
, 4.44 or 1E2) and incubated at different time points. A CD4 T-cell clone 352 
(5x10
3
, 4.44) was used as a readout for indirect allorecognition and a CD8 T-cell clone 353 
(5x10
3
, 1E2) for direct/semi-direct allorecognition. Part of the supernatant was harvested 354 
and cells were pulsed with 0.5µCi 
3
H (Life science products Inc. USA) and incubated for 355 
24h. Similarly (1x10
5
) PBMCs were co-cultured with (5x10
3
) T-cells (4.44 or 1E2) with 356 
different concentrations of HLA-A2. Co-cultures were incubated for 48h, supernatants 357 
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collected and cells pulsed with 
3
H for another 24h when proliferation was measured. 358 
Inhibition of indirect allorecognition was achieved by titration of mouse anti-human 359 
HLA-DR (B8.11.2, IgG2b) antibodies to the co-cultures. 360 
361 
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Figure legends: 553 
Figure 1. T-cell clones recognize cellular fragments through semi-direct 554 
allorecognition but not through indirect allorecognition. A) 5x10
3
 CD4 T-cells (4.44) 555 
were cultured with their native ligand HLA-A2+/HLA-DR1+ EBV-LCLs. IFN-γ 556 
secretion was measured in the supernatants after 24h. B) HLA-A2-/HLA-DR1+ EBV-557 
LCLs were pulsed with different HLA-A2 derived peptides and co-cultured with 4.44 T-558 
cells. After 24h IFN-γ was measured in the supernatants. C) An HLA-A2 recognizing 559 
CD8 T-cell clone (1E2) and the 4.44 were co-cultured with K562 or HLA-A2 transfected 560 
K562 cells (SAL-A2) for 48h. Supernatants were then collected and IFN-γ measured. D) 561 
HLA-Typed moDC (HLA-DR1+/HLA-A2-) were cultured with or without fragments of 562 
SAL-A2 cells (1:1 ratio at 5x10
4
 cells) for 48h after which 5x10
3
 4.44 T-cells were added 563 
with or without HLA-A2 peptides. E) moDCs were also cultured with 1E2 cells (as 564 
described in D). All experiments were repeated three times, graphs represent the mean 565 
+SD of a single experiment conducted in triplicate. Dashed lines represent the detection 566 
limit of the ELISA used.  567 
 568 
Figure 2. T-cell clones recognize necrotic cells through semi-direct allorecognition 569 
but not through indirect allorecognition. A-B) SAL-A2 cells were stained with HLA-570 
A2-PE labeled antibodies or isotype control. Cells were either viable or necrotic. IFN-γ 571 
stimulated SAL-A2 cells were stimulated with 100ng/ml IFN-γ for 24h prior to HLA-A2 572 
labeling. C-D) moDCs were labeled with PKH26 and SAL-A2 cells were labeled with 573 
CFSE. Necrosis was then induced and as a control viable cells were used. 1x10^4 SAL-574 
A2 cells were incubated in a 1:1 ratio with moDCs for 2 or 24h. Uptake of necrotic cells 575 
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by moDCs was quantified by flow cytometry double positive populations in the dotplots 576 
represent phagocytosis by moDCs which was also confirmed by confocal microscopy. E) 577 
Typed moDC (HLA-DR1+/HLA-A2-) were cultured with living/necrotic or IFN-γ 578 
stimulated necrotic SAL-A2 cells (1:1 ratio at 5x10
4
 cells) for 48h after which 5x10
3
 4.44 579 
T-cells were added with or without HLA-A2 peptides. F) moDCs were also cultured with 580 
1E2 cells (as described in E). All experiments were repeated three times, graphs represent 581 
mean + SD of a single experiment conducted in triplicate. Confocal imaging was repeated 582 
twice. Dashed bar depicts the detection limit. 583 
 584 
Figure 3. moDCs and monocytes present monomers to T-cells clones in a time and 585 
dose dependent manner. A-B) HLA-DR1+/HLA-A2- moDCs were incubated with 586 
HLA-A2 derived peptides(peptide pulsed) or HLA-A2 monomers(HLA-A2) in co-587 
cultures with or without the 4.44 T-cells for 24h. Supernatants were collected and IFN-γ 588 
measured. HLA-A2- moDCs presented HLA-A2 monomer derived peptides in a dose 589 
dependent manner to the T-cells. C) HLA-Typed moDCs were incubated with HLA-A2 590 
monomers for 1,2,4 and 6h, then washed thoroughly before the 4.44 T-cells were added 591 
for an additional 24h incubation. After a 24h incubation IFN-γ was measured in the 592 
supernatants D) HLA-Typed moDCs were incubated with HLA-A2 monomers for 4h and 593 
then thoroughly washed. T-cells were then added immediately (0h), 24h or after 48h. 594 
Supernatants were harvested after 24h. E-F) HLA-DR1+/HLA-A2- monocytes were 595 
pulsed with an HLA-A2 derived peptide or different concentrations of monomers (HLA-596 
A2) and co-cultured in the presence or absence of  4.44 T-cells. After 24h incubation 597 
IFN-γ was measured in the supernatants. All experiments were conducted in triplicate, 598 
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results indicate the mean + SD of one experiment in triplicate. Dashed bars indicate the 599 
detection limit of the ELISA used. ND – Not detectable. 600 
 601 
Figure 4. PBMCs can present HLA-A2 monomer derived peptides via HLA-DR1 602 
with no measurable semi-direct alloreactivity. A-B) 1x10
5
 Typed HLA-DR1+/HLA-603 
A2- PBMCs were incubated with different concentrations of HLA-A2 monomers or 604 
pulsed with an HLA-A2 peptide and co-cultured with or without 5x10
3
 4.44 T-cells. 48h 605 
after incubation supernatants were collected and IFN-γ measured. C-D) PBMCs were 606 
incubated with different concentrations of HLA-A2 monomers and co-cultured with 607 
either the indirect recognizing clone 4.44 (grey circles) or with the direct recognizing 608 
clone 1E2 (white circles) for 48h. IFN-γ and proliferation were analyzed as previously 609 
described. E) Different PBMC numbers were incubated with 25µg/ml HLA-A2 in the 610 
presence of 5x10
3
 4.44 for 24 or 48h. Supernatants were then harvested and IFN-γ 611 
measured. F) To test the minimal amount of T-cells needed to detect a response 4.44 were 612 
titrated and 25µg/ml HLA-A2 monomer was added in combination with 1x10
5
 HLA-613 
typed PBMCs for 48h. Supernatants were then collected and IFN-γ measured G-H) 614 
PBMCs were co-cultured with 4.44 T-cells in the presence of 25µg/ml HLA-A2 for 24h 615 
with or without anti-HLA-DR monoclonal antibodies (mAb). The reciprocal dilution of 616 
the HLA-DR mAb is set on the x-axis. All experiments were conducted at least 3 times 617 
shown is the mean + SD of one experiment in triplicate. Dashed line represents the 618 
detection limit of the ELISA used. ND – Not detectable.  619 
 620 
 621 
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Figure 1. T-cell clones recognize cellular fragments through semi-direct allorecognition but not through 
indirect allorecognition. A) 5x103 CD4 T-cells (4.44) were cultured with their native ligand HLA-A2+/HLA-
DR1+ EBV-LCLs. IFN-γ secretion was measured in the supernatants after 24h. B) HLA-A2-/HLA-DR1+ EBV-
LCLs were pulsed with different HLA-A2 derived peptides and co-cultured with 4.44 T-cells. After 24h IFN-γ 
was measured in the supernatants. C) An HLA-A2 recognizing CD8 T-cell clone (1E2) and the 4.44 were co-
cultured with K562 or HLA-A2 transfected K562 cells (SAL-A2) for 48h. Supernatants were then collected 
and IFN-γ measured. D) HLA-Typed moDC (HLA-DR1+/HLA-A2-) were cultured with or without fragments of 
SAL-A2 cells (1:1 ratio at 5x104 cells) for 48h after which 5x103 4.44 T-cells were added with or without 
HLA-A2 peptides. E) moDCs were also cultured with 1E2 cells (as described in D). All experiments were 
repeated three times, graphs represent the mean +SD of a single experiment conducted in triplicate. 
Dashed lines represent the detection limit of the ELISA used.  
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Figure 2. T-cell clones recognize necrotic cells through semi-direct allorecognition but not through indirect 
allorecognition. A-B) SAL-A2 cells were stained with HLA-A2-PE labeled antibodies or isotype control. Cells 
were either viable or necrotic. IFN-γ stimulated SAL-A2 cells were stimulated with 100ng/ml IFN-γ for 24h 
prior to HLA-A2 labeling. C-D) moDCs were labeled with PKH26 and SAL-A2 cells were labeled with CFSE. 
Necrosis was then induced and as a control viable cells were used. 1x10^4 SAL-A2 cells were incubated in a 
1:1 ratio with moDCs for 2 or 24h. Uptake of necrotic cells by moDCs was quantified by flow cytometry 
double positive populations in the dotplots represent phagocytosis by moDCs which was also confirmed by 
confocal microscopy. E) Typed moDC (HLA-DR1+/HLA-A2-) were cultured with living/necrotic or IFN-γ 
stimulated necrotic SAL-A2 cells (1:1 ratio at 5x104 cells) for 48h after which 5x103 4.44 T-cells were 
added with or without HLA-A2 peptides. F) moDCs were also cultured with 1E2 cells (as described in E). All 
experiments were repeated three times, graphs represent mean + SD of a single experiment conducted in 
triplicate. Confocal imaging was repeated twice. Dashed bar depicts the detection limit.  
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Figure 3. moDCs and monocytes present monomers to T-cells clones in a time and dose dependent manner. 
A-B) HLA-DR1+/HLA-A2- moDCs were incubated with HLA-A2 derived peptides(peptide pulsed) or HLA-A2 
monomers(HLA-A2) in co-cultures with or without the 4.44 T-cells for 24h. Supernatants were collected and 
IFN-γ measured. HLA-A2- moDCs presented HLA-A2 monomer derived peptides in a dose dependent 
manner to the T-cells. C) HLA-Typed moDCs were incubated with HLA-A2 monomers for 1,2,4 and 6h, then 
washed thoroughly before the 4.44 T-cells were added for an additional 24h incubation. After a 24h 
incubation IFN-γ was measured in the supernatants D) HLA-Typed moDCs were incubated with HLA-A2 
monomers for 4h and then thoroughly washed. T-cells were then added immediately (0h), 24h or after 48h. 
Supernatants were harvested after 24h. E-F) HLA-DR1+/HLA-A2- monocytes were pulsed with an HLA-A2 
derived peptide or different concentrations of monomers (HLA-A2) and co-cultured in the presence or 
absence of  4.44 T-cells. After 24h incubation IFN-γ was measured in the supernatants. All experiments 
were conducted in triplicate, results indicate the mean + SD of one experiment in triplicate. Dashed bars 
indicate the detection limit of the ELISA used. ND – Not detectable.  
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Figure 4. PBMCs can present HLA-A2 monomer derived peptides via HLA-DR1 with no measurable semi-
direct alloreactivity. A-B) 1x105 Typed HLA-DR1+/HLA-A2- PBMCs were incubated with different 
concentrations of HLA-A2 monomers or pulsed with an HLA-A2 peptide and co-cultured with or without 
5x103 4.44 T-cells. 48h after incubation supernatants were collected and IFN-γ measured. C-D) PBMCs were 
incubated with different concentrations of HLA-A2 monomers and co-cultured with either the indirect 
recognizing clone 4.44 (grey circles) or with the direct recognizing clone 1E2 (white circles) for 48h. IFN-γ 
and proliferation were analyzed as previously described. E) Different PBMC numbers were incubated with 
25µg/ml HLA-A2 in the presence of 5x103 4.44 for 24 or 48h. Supernatants were then harvested and IFN-γ 
measured. F) To test the minimal amount of T-cells needed to detect a response 4.44 were titrated and 
25µg/ml HLA-A2 monomer was added in combination with 1x105 HLA-typed PBMCs for 48h. Supernatants 
were then collected and IFN-γ measured G-H) PBMCs were co-cultured with 4.44 T-cells in the presence of 
25µg/ml HLA-A2 for 24h with or without anti-HLA-DR monoclonal antibodies (mAb). The reciprocal dilution 
of the HLA-DR mAb is set on the x-axis. All experiments were conducted at least 3 times shown is the mean 
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+ SD of one experiment in triplicate. Dashed line represents the detection limit of the ELISA used. ND – Not 
detectable.  
58x80mm (600 x 600 DPI)  
 
 
Page 33 of 31
ScholarOne support: (434) 964 4100
Transplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
